# TRULIEVE CANNABIS CORP. (TRLV) · Edgar & Edgarette company card

> Trulieve Cannabis (TRLV) saw revenue fall 0.4% in FY2025 to $1.2 billion, operating margin 12.1% against a 0.7% median for medicinal chemicals & botanical products, equity 42.4% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1754195 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/TRLV) · [JSON](https://www.pops4.com/boards/company/TRLV.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $1.2B |
| Revenue growth, 1 year | -0.4% |
| Revenue growth per year | 6.1% |
| Operating margin | 12.1% (prior year 8.2%) |
| Net margin | -10.3% |
| Operating cash flow | $273M |
| Capital spending | $44M |
| Free cash flow | $229M |
| Cash | $256M |
| Long-term debt | $137M |
| Total assets | $2.7B |
| Total equity | $1.1B |
| Equity ÷ assets | 42.4% |
| Return on equity | -10.7% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 1.09 (distress zone)
- Piotroski F: 6 of 9 (solid)
- Beneish M: -2.76 (below the −1.78 line)
- Health Harbor boat: Sound ship · one warning sign · slow and jumpy: growing slower than its size class, with revenue that swings more
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $1.2B (FY2025), total debt $136.7M. Experience: revenue down 0.4% on the year, up 6.1% a year over 4 years; operating margin 12.1%, up from 8.2%. Soundness: equity 42.4% of assets, return on equity -10.7%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $956.8M and $1.4B next year (method v4.1: its own 4-year record of growth weighed at 50% against $1B–10B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $838.8M to $1.6B. A statistical range, not company guidance. Against peers (10 filers, $50M+ revenue, medicinal chemicals & botanical products): operating margin 12.1% against a 0.7% median; growth -0.4% against 1.7%.

Range logged 2026-09-27, receipt 5f33c4eb287b38aa, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 5, latest 2026-07-02 ([filing](https://www.sec.gov/Archives/edgar/data/1754195/000175419526000056/0001754195-26-000056-index.htm))

## Recent filings

- 10-Q · filed 2026-11-05 · [filing](https://www.sec.gov/Archives/edgar/data/1754195/000175419526000089/0001754195-26-000089-index.htm)
- 8-K · filed 2026-11-05 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1754195/000175419526000087/0001754195-26-000087-index.htm)
- 8-K · filed 2026-08-11 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modifications to Rights of Security Holders; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1754195/000175419526000072/0001754195-26-000072-index.htm)
- 10-Q · filed 2026-08-07 · [filing](https://www.sec.gov/Archives/edgar/data/1754195/000175419526000069/0001754195-26-000069-index.htm)
- 8-K · filed 2026-08-07 · 2.01 Completion of Acquisition or Disposition of Assets; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1754195/000175419526000067/0001754195-26-000067-index.htm)
- 8-K · filed 2026-08-05 · 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1754195/000175419526000062/0001754195-26-000062-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001754195.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1754195

## Cite

POPS4, Edgar & Edgarette: TRULIEVE CANNABIS CORP. (TRLV) company card, from the company's own SEC filings, accessed 2026-11-12, https://www.pops4.com/boards/company/TRLV. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.